---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-120360"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:33:06.984765+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics acquires VLX-1005, a Phase 2 12-LOX inhibitor for HIT, from Veralox

## Summary
- Acquisition closed Dec 10, 2025; upfront cash $200K plus milestone payments up to $15M and 5% royalties on net sales.
- VLX-1005 is a first-in-class, potent 12-LOX inhibitor with FDA Orphan Drug and Fast Track designations for HIT.
- Phase 2 interim results demonstrated encouraging reductions in thromboembolic events; no deaths or serious AEs in Phase 1.
- HIT affects ~56,000 confirmed diagnoses annually in the U.S.; current therapies do not address immune-driven pathogenesis.
- Deal adds VLX-1005 to Cadrenal's anticoagulation pipeline alongside tecarfarin and frunexian, targeting $3B+ peak revenue potential.

## SEC filing metadata
- accession: 0001213900-25-120360
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390025120360/0001213900-25-120360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390025120360/ea0269180-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-120360
- JSON: https://secwatch.observer/filing/0001213900-25-120360.json
- Plain text: https://secwatch.observer/filing/0001213900-25-120360.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.